上海微知卓生物科技

Vitalink Biotech is a clinical-stage biotechnology company based in Shanghai, specializing in the development of bio-artificial liver systems and cell therapies for end-stage liver diseases. The company's core technology, the HepaCell platform, enables the large-scale expansion of functional human hepatocytes, addressing the critical shortage of donor organs. Its lead product, the Vitalink-BAL (Bio-artificial Liver), is designed to provide metabolic support and detoxification for patients with acute-on-chronic liver failure (ACLF). By integrating advanced cell engineering with extracorporeal device technology, Vitalink aims to bridge patients to transplant or facilitate spontaneous liver recovery. The company is also exploring broader applications of its hepatocyte technology in drug screening and metabolic disease treatment.